Cell Therapeutics stock was up after positive results from 91 percent target achievement rate was reported in the August issue of the American Journal of Clinical Oncology. Twelve patients with esophageal or gastric cancer has been tested with the cancer drug Xyotax.
Dr. Howard Safran of Brown University says that Xyotax may “replace paclitaxel as the most important radiation sensitizer in solid tumors”. If this is true, we may see a future without the need for or less side effects from chemotherapy drugs.
CTIC closed $1.61 on Thursday 24 August 2006.
- Cell Therapeutics to Submit New XYOTAX Drug Trial to FDA
- Cell Therapeutics Signs Deal With Norvatis
- Cell Therapeutics To Suspend Enrollment for PIONEER Drug Trial